Fig. 4.
Fig. 4. CD4+ cells are required for the generation of barrier activity in recipients. / (Left panel) B6-CD4−/− mice were primed against donor BALB.B MiHA 4 weeks prior to BM-TCD transplantation. Resistance in these CD4 knock-out animals was examined by CFU-IL3 analyses. (Right panel) Spleen + LN cells containing desired number of CD4+ cells were transferred from naive B6-wt mice into naive B6-CD4−/− recipient mice. Groups of B6-CD4−/− recipients received (1) no lymphocyte transfer prior to priming, (2) a lymphocyte transfer inoculum containing 5.7 × 106 wild-type CD4+cells, (3) a lymphocyte transfer inoculum containing 1.6 × 106 wild-type CD4+ cells, or (4) a lymphocyte transfer inoculum depleted of CD4+ cells (< 4 × 104 CD4+ cells) as described in “Materials and methods.” One day following transfer, the CD4−/− recipient mice were immunized against donor BALB.B cells. Three weeks after priming, the allograft resistance in these adoptively transferred B6-CD4−/− recipient groups were examined by CFU-IL3 assay following transplantation of 2 × 106 BALB.B BM-TCD.

CD4+ cells are required for the generation of barrier activity in recipients.

(Left panel) B6-CD4−/− mice were primed against donor BALB.B MiHA 4 weeks prior to BM-TCD transplantation. Resistance in these CD4 knock-out animals was examined by CFU-IL3 analyses. (Right panel) Spleen + LN cells containing desired number of CD4+ cells were transferred from naive B6-wt mice into naive B6-CD4−/− recipient mice. Groups of B6-CD4−/− recipients received (1) no lymphocyte transfer prior to priming, (2) a lymphocyte transfer inoculum containing 5.7 × 106 wild-type CD4+cells, (3) a lymphocyte transfer inoculum containing 1.6 × 106 wild-type CD4+ cells, or (4) a lymphocyte transfer inoculum depleted of CD4+ cells (< 4 × 104 CD4+ cells) as described in “Materials and methods.” One day following transfer, the CD4−/− recipient mice were immunized against donor BALB.B cells. Three weeks after priming, the allograft resistance in these adoptively transferred B6-CD4−/− recipient groups were examined by CFU-IL3 assay following transplantation of 2 × 106 BALB.B BM-TCD.

Close Modal

or Create an Account

Close Modal
Close Modal